Change in Board of Directors and Composition of Committees
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sun Pharma's Board has appointed Dr. Andreas Busch as an Independent Director for a 5-year term starting 12 May 2026, subject to shareholder approval. Dr. Busch, currently Chief Innovation Officer at Absci, brings extensive R&D experience from top pharma companies including Sanofi, Bayer, and Shire, having led development of over 15 FDA-approved drugs. Concurrently, Ms. Rama Bijapurkar will retire from the Board on 20 May 2026 upon completing her term as Independent Director. Ms. Satyavati Berera has been appointed to the Audit Committee and Risk Management Committee in place of the departing director.
The appointment of Dr. Busch, a globally recognized pharma R&D leader, strengthens the Board's technical expertise. The retirement of Ms. Bijapurkar appears routine as her term ends naturally. Overall, this is a routine board transition with no material governance concerns.